The University of Chicago Header Logo

Connection

Yusuke Nakamura to Immunotherapy

Back to Details
This is a "connection" page, showing publications Yusuke Nakamura has written about Immunotherapy.
Yusuke Nakamura
Connection Strength
4.230
Immunotherapy
  1. Immunogenomics in personalized cancer treatments. J Hum Genet. 2021 Sep; 66(9):901-907.
    View in: PubMed
    Score: 0.548
  2. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites. Immunol Invest. 2021 Jul; 50(5):562-579.
    View in: PubMed
    Score: 0.513
  3. The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. Jpn J Clin Oncol. 2019 Jul 01; 49(7):596-603.
    View in: PubMed
    Score: 0.477
  4. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci. 2018 Mar; 109(3):542-549.
    View in: PubMed
    Score: 0.434
  5. Characterization of the B-cell receptor repertoires in peanut allergic subjects undergoing oral immunotherapy. J Hum Genet. 2018 Feb; 63(2):239-248.
    View in: PubMed
    Score: 0.428
  6. Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy. Trends Pharmacol Sci. 2017 01; 38(1):15-24.
    View in: PubMed
    Score: 0.398
  7. Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 2016 Feb; 107(2):107-15.
    View in: PubMed
    Score: 0.377
  8. Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. Cancer Sci. 2005 Aug; 96(8):498-506.
    View in: PubMed
    Score: 0.182
  9. Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug; 41(8):4101-4115.
    View in: PubMed
    Score: 0.138
  10. Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]. Oncoimmunology. 2020 11 11; 9(1):1838189.
    View in: PubMed
    Score: 0.131
  11. The era of immunogenomics/immunopharmacogenomics. J Hum Genet. 2018 Jul; 63(8):865-875.
    View in: PubMed
    Score: 0.110
  12. A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors. PLoS One. 2018; 13(1):e0187878.
    View in: PubMed
    Score: 0.108
  13. Cancer vaccines. Clin Adv Hematol Oncol. 2011 Oct; 9(10):778-9.
    View in: PubMed
    Score: 0.070
  14. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int J Cancer. 2010 May 01; 126(9):2153-63.
    View in: PubMed
    Score: 0.063
  15. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res. 2008 Oct 15; 14(20):6487-95.
    View in: PubMed
    Score: 0.057
  16. Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15; 10(24):8577-86.
    View in: PubMed
    Score: 0.044
  17. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res. 2004 Oct 01; 10(19):6437-48.
    View in: PubMed
    Score: 0.043
  18. Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. J Immunother. 2018 May; 41(4):201-207.
    View in: PubMed
    Score: 0.028
  19. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Clin Cancer Res. 2013 Aug 15; 19(16):4508-20.
    View in: PubMed
    Score: 0.020
  20. [Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2268-70.
    View in: PubMed
    Score: 0.014
  21. [A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2271-3.
    View in: PubMed
    Score: 0.014
  22. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov; 98(11):1803-8.
    View in: PubMed
    Score: 0.013
  23. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006 May; 97(5):411-9.
    View in: PubMed
    Score: 0.012
  24. Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers. Oncol Rep. 2004 Aug; 12(2):275-80.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.